Continued Rebound: Trends in Life Science M&A


Published on

Published in: Economy & Finance, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Continued Rebound: Trends in Life Science M&A

  1. 1. Continued Rebound:Trends in Life Science M&ASilicon Valley BankJuly 2012Written By: yJonathan NorrisManaging 1
  2. 2. Agenda • Part I:Overview of 2011 Big Exits • Part II: Analysis by Indication o Series A Investment by Indication between 2005 and 2011 o LPI and Hit Rate – Measuring Indication Performance in the Life Science Industry 2
  3. 3. Overview of Big Exits 3
  4. 4. M&A Big Exits Per Year ( g (2005-2011) ) 4
  5. 5. Total Big Exit Dollar Volume g 5
  6. 6. Average Time to Exit g 6
  7. 7. Biotech Deal Type yp 7
  8. 8. Biotech Big Exits g 8
  9. 9. Biotech Structured Deal Breakdown 9
  10. 10. Biotech Breakdown by Stage, Round, Years to Exit y g , , 10
  11. 11. Biotech Upfront Payments by Stage in StructuredDeal Era (2009-2011) ( ) 11
  12. 12. Device Big Exits g 12
  13. 13. Device Structured Deal Breakdown 13
  14. 14. Device Stage Breakdown g 14
  15. 15. Device Capital Efficient Exits by Multiple p y p 15
  16. 16. Analysis By Indication y y 16
  17. 17. Life Science Series A Data 17
  18. 18. Biotech Series A Data 18
  19. 19. Device Series A Data 19
  20. 20. Life Science Investments by Indication y 20
  21. 21. Indication Breakdown: Biotech 21
  22. 22. Indication Breakdown: Med Device 22
  23. 23. Biotech Indication Performance Data 23
  24. 24. Device Indication Performance Data 24
  25. 25. Disclosures This material, including without limitation the statistical information herein, is provided for informational purposes only. The material is based in part upon information from third-party only sources that we believe to be reliable, but which has not been independently verified by us and, as such, we do not represent that the information is accurate or complete. The information should not be viewed as tax, investment, legal or other advice nor is it to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice b f f i l d i before making any i ki investment d i i t t decision. N thi relating t th material Nothing l ti to the t i l should be construed as a solicitation or offer, or recommendation, to acquire or dispose of any investment or to engage in any other transaction. U.S. VC-backed Service companies were included under the device category. Services represented l t d less th 10 percent of all d l i thi category. R ti than t f ll deals in this t Rational f i l di l for including Services was to try and capture as much U.S. LS Venture investment as possible - creating an additional category with a small data set did not make sense. ©2012 SVB Financial Group All rights reserved Member Federal Reserve System Group. reserved. System. SVB>, SVB>Find a way, SVB Financial Group, and Silicon Valley Bank are registered trademarks. B-12-12265. Rev. 07-16-12. 25